Introduction: Sorafenib is an orally active multiple kinase inhibitor for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma (HCC) patients. However, measuring the experience of patient-reported symptoms may provide additional information to compare the efficacy and toxicity of treatments. Objective: The aim of the current study was to investigate the association between hepatocellular carcinoma patients' adherence to treatment and their demographic characteristics. Patients and methods: An open-label cross-sectional study was conducted at the Oncology Teaching Hospital, Al-Amal Hospital, Imam Al-Kadhimin Medical City in Baghdad, Iraq, from November 2021 to July 2022. A total of 52 patients taking sorafenib for their HCC were recruited in our study. Adherence to treatment was assessed using Morisky Medication Adherence Scale. Results: A total of 52 patients were enrolled in current study. Fatigue was the most common adverse event as it was experienced by 90.4% of participants, followed by anorexia, anemia, nausea and diarrhea (71.2%, 67.3%, 65.4%, and 59.6%, respectively), while only 26.9% of participants had vomiting. In addition, all participants showed low-moderate adherence to treatment. Also, there was non-significant association between demographic data of patients or treatment-related adverse effects. Conclusion: Patients with hepatocellular carcinoma on sorafenib treatment exhibit low-moderate levels of adherence. The latter had not affected by sorafenib-related adverse effects or demographic characteristics of patients.